Published in Oncogene on May 24, 2004
Modes of p53 regulation. Cell (2009) 9.31
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Epigenetic reprogramming in cancer. Science (2013) 3.47
miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol (2010) 2.29
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol (2008) 1.72
The impact of acetylation and deacetylation on the p53 pathway. Protein Cell (2011) 1.66
Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol (2007) 1.43
CBP binding outside of promoters and enhancers in Drosophila melanogaster. Epigenetics Chromatin (2015) 1.41
Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol (2007) 1.39
An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. J Biol Chem (2008) 1.34
Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res (2010) 1.25
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells. Blood (2006) 1.21
Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4. Biochemistry (2013) 1.17
Crif1 is a novel transcriptional coactivator of STAT3. EMBO J (2008) 1.16
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol (2011) 1.14
Roles for the coactivators CBP and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent cell transformation. Br J Cancer (2006) 1.14
Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. Genes Dev (2011) 1.12
Histone modifiers in cancer: friends or foes? Genes Cancer (2011) 1.10
The coactivators CBP/p300 and the histone chaperone NAP1 promote transcription-independent nucleosome eviction at the HTLV-1 promoter. Proc Natl Acad Sci U S A (2008) 1.10
Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog (2011) 1.10
Cancer epigenetics: a brief review. ILAR J (2012) 1.09
Use of epigenetic drugs in disease: an overview. Genet Epigenet (2014) 1.08
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett (2009) 1.06
Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol (2010) 1.05
A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett (2007) 1.03
Role of HDAC1 in senescence, aging, and cancer. Exp Gerontol (2009) 1.02
Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int (2012) 1.02
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
Decreased nuclear expression and increased cytoplasmic expression of ING5 may be linked to tumorigenesis and progression in human head and neck squamous cell carcinoma. J Cancer Res Clin Oncol (2010) 1.01
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. Br J Cancer (2006) 1.00
Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem (2011) 1.00
Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis. J Biol Chem (2012) 0.99
Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem (2010) 0.99
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
Prepaying the entropic cost for allosteric regulation in KIX. Proc Natl Acad Sci U S A (2014) 0.98
SAMNet: a network-based approach to integrate multi-dimensional high throughput datasets. Integr Biol (Camb) (2012) 0.98
BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300. Cancer Res (2012) 0.97
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem (2010) 0.97
Host epigenetic modifications by oncogenic viruses. Br J Cancer (2006) 0.97
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res (2015) 0.97
Genomic occupancy of the transcriptional co-activators p300 and CBP. Transcription (2012) 0.97
p53 Acetylation: Regulation and Consequences. Cancers (Basel) (2014) 0.97
Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer. J Biol Chem (2012) 0.96
Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol (2013) 0.96
Is histone acetylation the most important physiological function for CBP and p300? Aging (Albany NY) (2012) 0.95
p85α mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response. Oncogene (2010) 0.95
AP-1 mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon β. PLoS One (2012) 0.95
Mining functional subgraphs from cancer protein-protein interaction networks. BMC Syst Biol (2012) 0.94
The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res (2007) 0.94
MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol (2011) 0.93
In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Br J Cancer (2012) 0.93
TLX1/HOX11-induced hematopoietic differentiation blockade. Oncogene (2007) 0.91
Synergistic activation of human involucrin gene expression by Fra-1 and p300--evidence for the presence of a multiprotein complex. J Invest Dermatol (2007) 0.91
The histone acetyltransferases CBP/p300 are degraded in NIH 3T3 cells by activation of Ras signalling pathway. Biochem J (2006) 0.91
p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. J Invest Dermatol (2013) 0.91
An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev (2013) 0.90
Dynamics of re-constitution of the human nuclear proteome after cell division is regulated by NLS-adjacent phosphorylation. Cell Cycle (2014) 0.89
A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. BMC Cancer (2014) 0.88
Epigenetic mechanisms in virus-induced tumorigenesis. Clin Epigenetics (2011) 0.88
Targeting epigenetic regulations in cancer. Acta Biochim Biophys Sin (Shanghai) (2015) 0.88
Cooperation of p300 and PCAF in the control of microRNA 200c/141 transcription and epithelial characteristics. PLoS One (2012) 0.88
Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology (2016) 0.87
Transcription coactivators p300 and CBP are necessary for photoreceptor-specific chromatin organization and gene expression. PLoS One (2013) 0.86
Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2. Oncotarget (2012) 0.86
Targeting of histone acetyltransferase p300 by cyclopentenone prostaglandin Δ(12)-PGJ(2) through covalent binding to Cys(1438). Chem Res Toxicol (2011) 0.86
Epigenetic mechanisms of Rubinstein-Taybi syndrome. Neuromolecular Med (2014) 0.86
Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol Oncol (2012) 0.86
Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56. J Biol Chem (2012) 0.85
Perturbation of mitosis through inhibition of histone acetyltransferases: the key to ochratoxin a toxicity and carcinogenicity? Toxicol Sci (2011) 0.85
Demystifying the secret mission of enhancers: linking distal regulatory elements to target genes. Crit Rev Biochem Mol Biol (2015) 0.85
Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition. Chembiochem (2012) 0.85
The interaction of MYC with the trithorax protein ASH2L promotes gene transcription by regulating H3K27 modification. Nucleic Acids Res (2014) 0.85
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife (2016) 0.84
FANCJ/BACH1 acetylation at lysine 1249 regulates the DNA damage response. PLoS Genet (2012) 0.84
The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis. Int J Mol Sci (2016) 0.83
The HTLV-1-encoded protein HBZ directly inhibits the acetyl transferase activity of p300/CBP. Nucleic Acids Res (2012) 0.83
Regulation of histone modifying enzymes by the ubiquitin-proteasome system. Biochim Biophys Acta (2014) 0.83
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget (2016) 0.83
Transcriptional tools: Small molecules for modulating CBP KIX-dependent transcriptional activators. Biopolymers (2011) 0.82
Epigenetic regulation of inflammatory gene expression in macrophages by selenium. J Nutr Biochem (2014) 0.82
Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation. Proc Natl Acad Sci U S A (2014) 0.81
A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells. Nucleic Acids Res (2015) 0.81
A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett (2011) 0.81
p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol (2007) 0.81
Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nat Rev Cancer (2016) 0.80
The CH2 domain of CBP/p300 is a novel zinc finger. FEBS Lett (2013) 0.80
The histone acetyltransferase p300 regulates the expression of pluripotency factors and odontogenic differentiation of human dental pulp cells. PLoS One (2014) 0.80
Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol (2010) 0.80
Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. PLoS One (2013) 0.79
The effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines. Adv Biomed Res (2013) 0.79
Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J (2015) 0.79
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res (2014) 2.25
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol (2006) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer. Bioinformatics (2006) 2.12
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell (2007) 2.05
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol (2010) 2.01
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res (2012) 1.95
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
Cancer genetics of epigenetic genes. Hum Mol Genet (2007) 1.72
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res (2006) 1.71
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. J Pathol (2010) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer (2005) 1.62
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics (2009) 1.55
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res (2010) 1.55
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res (2008) 1.54
p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A (2004) 1.53
Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol (2007) 1.51
Disruption of ALX1 causes extreme microphthalmia and severe facial clefting: expanding the spectrum of autosomal-recessive ALX-related frontonasal dysplasia. Am J Hum Genet (2010) 1.49
A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat (2002) 1.44
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology (2010) 1.43
Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol (2003) 1.43
Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res (2009) 1.42
Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet (2003) 1.42
Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci U S A (2007) 1.41
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet (2009) 1.39
Fine scale mapping of the breast cancer 16q12 locus. Hum Mol Genet (2010) 1.39
Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol (2014) 1.38
Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays. Appl Immunohistochem Mol Morphol (2016) 1.38
Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol (2007) 1.36
A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. Bioinformatics (2005) 1.36
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. Cancer Res (2007) 1.33
Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res (2006) 1.31
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res (2010) 1.31
Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res (2011) 1.29
Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res (2008) 1.28
TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer. Nat Commun (2012) 1.23
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol (2011) 1.23
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer (2010) 1.22
Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics (2009) 1.21
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol (2012) 1.21
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 1.20
Improving breast cancer survival analysis through competition-based multidimensional modeling. PLoS Comput Biol (2013) 1.20
Screening of 38 genes identifies mutations in 62% of families with nonsyndromic deafness in Turkey. Genet Test Mol Biomarkers (2010) 1.20
Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping. BMC Med Genomics (2012) 1.20
Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol (2005) 1.19
Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. Breast Cancer Res (2009) 1.16
Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer (2009) 1.15
Micro-RNAs and breast cancer. Mol Oncol (2010) 1.13
Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun (2013) 1.12
Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol (2012) 1.12